Cogent Biosciences Q2 EPS $(0.59) Misses $(0.56) Estimate
Portfolio Pulse from Benzinga Newsdesk
Cogent Biosciences (NASDAQ:COGT) reported a Q2 EPS of $(0.59), missing the analyst consensus estimate of $(0.56) by 5.36%. This result is unchanged from the same period last year.
August 06, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cogent Biosciences reported a Q2 EPS of $(0.59), missing the analyst estimate of $(0.56) by 5.36%. The result is unchanged from the same period last year, indicating no improvement in financial performance.
The missed earnings estimate and lack of improvement from the same period last year suggest potential negative sentiment among investors, likely leading to a short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100